CD274 and Hodgkins lymphoma: Nivolumab, a human IgG4 mAb, blocks the interaction of PD-L1 and PD-L2 by binding to the PD-1 receptor on activated immune cells, which was already approved by the FDA in 2016 for the treatment of relapsed or progressed HL (75).